What does the weighted average price mean in Jason Aryeh’s OBIO share purchase?

The weighted average price of $3.90 means Aryeh’s 8,971 shares were bought through multiple trades at different prices. Individual transaction prices ranged from $3.70 to $4.03 per share, and the volume-weighted combination of those trades produced the reported $3.90 average.

Director at Orchestra BioMed (OBIO) buys 8,971 shares in open market

Filing Impact

(Neutral)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Orchestra BioMed Holdings director Jason Aryeh bought additional company stock in the open market. On May 15, 2026, he purchased 8,971 shares of common stock at a weighted average price of $3.90 per share, through multiple trades priced between $3.70 and $4.03.

Following this transaction, Aryeh directly owns 117,453 shares of Orchestra BioMed common stock. The filing notes that detailed trade-by-trade pricing within this range is available on request from the company, its shareholders, or the SEC staff.

Insider Trade Summary

Net Buyer: 8,971 shares ($34,987)

Net Buy 1 txn

Insider Aryeh Jason

Role null

Bought 8,971 shs ($35K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share	8,971	$3.90	$35K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 117,453 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares purchased: 8,971 shares Weighted average price: $3.90 per share Price range: $3.70–$4.03 per share +2 more

5 metrics

Shares purchased 8,971 shares Open-market purchase on May 15, 2026

Weighted average price $3.90 per share Price for 8,971-share purchase

Price range $3.70–$4.03 per share Individual trade prices within the purchase

Shares owned after 117,453 shares Direct holdings following the transaction

Net buy shares 8,971 shares Net change from this Form 4, all purchases

Key Terms

open-market purchase, weighted average price, Common Stock, par value $0.0001 per share, Form 4

4 terms

open-market purchase financial

"transaction_action is described as an open-market purchase of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

weighted average price financial

"The price reported is a weighted average price for the multiple trades"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 regulatory

"The insider transaction is reported on a Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

05/19/2026 - 08:00 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aryeh Jason

(Last)

(First)

(Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE

PENNSYLVANIA

18938

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.0001 per share	05/15/2026		P		8,971	A	$3.9⁽¹⁾	117,453	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $4.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Andrew Taylor, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Jason Aryeh report for Orchestra BioMed (OBIO)?

Jason Aryeh reported an open-market purchase of Orchestra BioMed common stock. He bought 8,971 shares on May 15, 2026 at a weighted average price of $3.90 per share, increasing his direct holdings to 117,453 shares after the transaction.

How many Orchestra BioMed (OBIO) shares did Jason Aryeh buy and at what price?

Jason Aryeh bought 8,971 shares of Orchestra BioMed common stock. The weighted average purchase price was $3.90 per share, with individual trades executed in a price range between $3.70 and $4.03 according to the Form 4 footnote.

What are Jason Aryeh’s Orchestra BioMed (OBIO) holdings after this Form 4 trade?

After the reported open-market purchase, Jason Aryeh directly owns 117,453 Orchestra BioMed common shares. This figure reflects his position immediately following the May 15, 2026 acquisition of 8,971 additional shares at a weighted average price of $3.90 per share.

What type of transaction was disclosed in the Orchestra BioMed (OBIO) Form 4?

The Form 4 discloses a non-derivative, open-market purchase of common stock. Director Jason Aryeh bought 8,971 Orchestra BioMed shares on May 15, 2026 at a weighted average price of $3.90, rather than receiving them as compensation or through derivative exercises.